General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Xylocor(SIGNIFICANT) OTHER FINANCIAL BENEFIT: Merck(SIGNIFICANT), NovoNordisc(SIGNIFICANT), Relypsa(SIGNIFICANT), Daiichi Sankyo(SIGNIFICANT)

View Full Disclosure